Alluvi Reta Pen 

Alluvi Reta Pen A pre-filled research device containing a 20 mg version of tirzepatide, only for use in controlled laboratory research and development. Alluvi Reta Pen is supplied in a sealed condition to aid in formulation research, delivery method assessment, and compound stability analysis.

Produced exclusively for laboratory research. Not for use by humans or animals.

A pre-filled research pen with 20 mg of tirzepatide and a research information page are included in every 20 mg research kit.

Alluvi Reta

Storage: Keep chilled (between 2 and 8°C). Avoid freezing.
supplied for laboratory analysis in a sealed, fixed-volume packaging.

Delivery: A cold pack was sent out.
tracked delivery to the UK in two days.

Tirzepatide 20MG Dosage

Many jurisdictions have allowed dosages of up to 15 mg once weekly for the human-use drug tirzepatide (marketed under brand names as Mounjaro).

 Tirzepatide 20mg Pen | Reta Pen Uk

Retatrutide and Tirzepatide 20mg pens from Alluvi are research-grade peptide formulations intended solely for use in laboratories, not for ingestion by humans or animals.

Alluvi Retatrutide 20mg Pen Overview | 20mg Reta Pen

• The Retatrutide 20mg pen is part of Alluvi Healthcare’s investigation into GLP-1 multi-agonist drugs and is only supplied for restricted laboratory R&D uses.
• Formulation: A research information leaflet and a pre-filled research pen with 20 milligrams of retatrutide are included with every kit.
• Use Case: Designed for research on formulation behavior, compound stability, and delivery mechanism assessment